Quantification of Teprenone in Human Plasma by HPLC Coupled to Mass Spectrometry: Application to a Bioequivalence Study
A rapid, sensitive, and specific method has been developed for quantification of teprenone (TEP) in human plasma. The analytes were isolated from plasma by liquid-liquid extraction with t-butyl methyl ether. The extracts were analyzed by high-performance liquid chromatography coupled to mass spectro...
Saved in:
Published in | Chromatographia Vol. 65; no. 9-10; pp. 533 - 538 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Wiesbaden : Vieweg Verlag
01.05.2007
Springer |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | A rapid, sensitive, and specific method has been developed for quantification of teprenone (TEP) in human plasma. The analytes were isolated from plasma by liquid-liquid extraction with t-butyl methyl ether. The extracts were analyzed by high-performance liquid chromatography coupled to mass spectrometry (HPLC-MS); gefarnate was used as internal standard (IS). HPLC separation of the analytes was performed on a C₁₈ column with 1:54:45 (v/v) 1% aqueous acetic acid-methanol-acetonitrile as mobile phase; the flow rate was 0.2 mL min-¹. The compounds were ionized by atmospheric-pressure chemical ionization (APCI). Calibration plots for TEP were linear in the range 20.0-2000.0 ng mL-¹; correlation coefficients were >0.9981. The average extraction efficiency for TEP was >67%, method recovery was >95%, the limit of detection (LOD) was 1.0 ng mL-¹, and the intraday and interday coefficients of variation were <7%. This HPLC-MS procedure was used to assess the bioequivalence of TEP tablet and capsule formulations. A single 150-mg dose of each formulation was administered to 18 healthy male volunteers. The study was conducted using an open, randomized, two-period crossover design with a 1-week wash-out interval. Because the 90% CI for C max and the ratios of the AUCs were all within the 80-125% range stipulated by the US Food and Drug Administration, it was concluded that the TEP tablet and capsule formulations were bioequivalent in terms of rate and extent of absorption. |
---|---|
Bibliography: | http://dx.doi.org/10.1365/s10337-007-0188-8 |
ISSN: | 0009-5893 1612-1112 |
DOI: | 10.1016/S0009-5893(07)82057-1 |